| Literature DB >> 33157042 |
Tian Y Zhang1, Ravindra Majeti2.
Abstract
Most patients with AML succumb to chemoresistant leukemia stem cells (LSCs), which persist and reinitiate disease years after clinical remission. In this issue of Cell Stem Cell, Jones et al. (2020) identify a therapeutically targetable mechanism of resistance to venetoclax in relapsed and refractory AML LSCs mediated by nicotinamide metabolism.Entities:
Year: 2020 PMID： 33157042 DOI： 10.1016/j.stem.2020.10.007
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633